FDA Approves Treosulfan with Fludarabine As a Preparative Regimen for alloHSCT in Adult and Paediatric Patients with AML or MDS By Ogkologos - March 13, 2025 723 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the MC-FludT.14/L Trial II Source RELATED ARTICLESMORE FROM AUTHOR New Survey Highlights the Role of Clinical Practice Guidelines to Improve Care for Patients with Rare Cancers FDA Grants Traditional Approval to Encorafenib for mCRC with a BRAF V600E Mutation In Memory of Hernán Cortés-Funes: Former ESMO President and Pioneer in Medical Oncology MOST POPULAR Trial Results Support Adding Daratumumab to Initial Treatment for Multiple Myeloma January 19, 2024 FDA Approves Neoadjuvant/Adjuvant Durvalumab for Patients with Resectable NSCLC September 18, 2024 New on NCI Websites for December 2018 December 28, 2018 EMA Recommends Extension of Indications for Talazoparib November 27, 2023 Load more HOT NEWS Peace Inavolisib Plus Palbociclib-Fulvestrant Prolongs OS in Patients with PIK3CA-Mutated Advanced Breast Cancer 什么是癌症的肿瘤标志物检测？您需要需要知道的 8 件事 Machine Learning-Based Model Shows Promise for Indicating Response to Immune Checkpoint...
